Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 1.18TCr 1.02TCr 953.53Cr 871.48Cr 1.64TCr 1,12400Cr 1.67TCr 11TCr 4.39TCr 56TCr 4.42TCr 4.33TCr 1,87300Cr P/E 2026 *
-80.8x
P/E 2027 * 81x
Enterprise Value 1.13TCr 974.74Cr 911.09Cr 832.69Cr 1.57TCr 1,07400Cr 1.59TCr 11TCr 4.19TCr 54TCr 4.23TCr 4.14TCr 1,78900Cr EV / Sales 2026 *
7.38x
EV / Sales 2027 * 5.05x
Free-Float
94.13%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week+6.55%
Current month+9.90%
1 month-4.31%
3 months+3.33%
6 months+7.26%
Current year-11.81%
1 week 489.23
Extreme 489.23
524.45
1 month 447.01
Extreme 447.01
566.18
Current year 416.21
Extreme 416.21
598.79
1 year 342.73
Extreme 342.733
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 7.27
Extreme 7.27
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/06/26 Free

Director

1,220 0.0053%
23/02/26 Fiscal year

Director

5,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%+6.55%+46.94%+199.09% 1.18TCr
+4.21%+25.62%+77.96%+111.62% 6.81TCr
+0.50%+6.20%+38.65%+67.83% 5.52TCr
+2.83%+35.25%+17.95%+486.05% 2.86TCr
+0.57%+19.05%+57.08%+5.18% 2.4TCr
-0.94%+1.08%-14.65%-11.58% 2.35TCr
-0.35%+7.91%+46.74%-22.61% 1.84TCr
-2.04%+9.24%+31.14%+650.71% 1.64TCr
+7.26%+25.47%+221.03%+383.67% 1.58TCr
-2.20%-4.40%+40.70%+148.87% 1.34TCr
Average +0.99%+11.10%+56.35%+201.88% 2.75TCr
Weighted average by Cap. +1.52%+11.53%+54.31%+166.36%

Financials

2026 *2027 *
Net sales 152.63Cr 132.13Cr 123.5Cr 112.88Cr 212.71Cr 15TCr 216.03Cr 1.45TCr 568.29Cr 7.28TCr 573.11Cr 560.61Cr 24TCr 214.49Cr 185.68Cr 173.56Cr 158.62Cr 298.91Cr 20TCr 303.59Cr 2.04TCr 798.6Cr 10TCr 805.38Cr 787.82Cr 34TCr
Net income -18Cr -16Cr -15Cr -14Cr -26Cr -1.75TCr -26Cr -174.47Cr -68Cr -877.29Cr -69Cr -68Cr -2.92TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 189.77Cr 74Cr 954.24Cr 75Cr 73Cr 3.18TCr
Net Debt -52Cr -45Cr -42Cr -39Cr -73Cr -5TCr -74Cr -497.7Cr -195.3Cr -2.5TCr -196.95Cr -192.66Cr -8.34TCr -94Cr -82Cr -76Cr -70Cr -131.45Cr -9TCr -133.5Cr -894.99Cr -351.19Cr -4.5TCr -354.17Cr -346.44Cr -15TCr
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
11/26/11 $515.34 +1.04% 2,72,850
07/26/07 $510.04 -0.06% 3,47,529
06/26/06 $510.36 -0.73% 2,96,763
05/26/05 $514.12 +1.29% 3,49,534
04/26/04 $507.56 +5.30% 4,42,367
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
510.04USD
Average target price
678.06USD
Spread / Average Target
+32.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock